InvestorsHub Logo
Followers 55
Posts 2608
Boards Moderated 0
Alias Born 02/04/2014

Re: BioNewton post# 41869

Monday, 10/12/2015 4:24:53 PM

Monday, October 12, 2015 4:24:53 PM

Post# of 144814
And this was reported after the first clinical study...

"Preliminary data analysis suggests that treatment with Nuvilex's live-cell encapsulation technology, Cell-in-a-Box® plus ifosfamide, produces a significant survival advantage as compared to non-treated control animals. Nuvilex's treatment appears to be at least as good as cisplatin, the current standard of care for ovarian cancer. However, when the encapsulated cells plus ifosfamide were used in conjunction with cisplatin, the survival rate was greatly enhanced. The final data analysis will be released in the future."

http://globenewswire.com/news-release/2014/11/19/684617/10108949/en/Nuvilex-Announces-Preliminary-Data-From-Preclinical-Study-of-Effects-of-Its-Pancreatic-Cancer-Treatment-on-Ascites-Fluid-Formation.html#sthash.y2R72xy4.dpuf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News